StockNews.AI
TECH
StockNews.AI
148 days

Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting

1. Bio-Techne advances RNAscope technology for biomarker detection. 2. Seminar at USCAP will showcase these innovations in pathology labs. 3. Pathologists will present RNAscope's benefits over traditional methods. 4. Potential to reduce result times and improve biomarker detection. 5. Bio-Techne generated $1.2 billion in net sales in fiscal 2024.

6m saved
Insight
Article

FAQ

Why Bullish?

The advancements and future applications of RNAscope technology could lead to increased revenue and stock value for TECH, similar to past technology upgrades in biotech that positively affected company valuations.

How important is it?

The focus on innovative technologies and clinical advancements plays a critical role in not just enhancing current market standing but also in future growth prospects, underlining its strategic importance.

Why Long Term?

As the adoption of RNAscope technology expands in clinical settings, long-term revenue growth is expected, akin to other medical technology advancements that require time to integrate into practice.

Related Companies

ACDALDXREGNAMGNILMN
, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place from March 22-27 in Boston, MA. Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will be exhibiting and showcasing RNAscope technology at booth #222. Leading pathologists will describe how they have used RNAscope technology to detect clinically relevant biomarkers, including secreted proteins, point mutations and chromosomal translocations, with the potential to improve performance over existing methods and reduce time to results. The session "RNAscope: Lightning Lunch and Learn" at noon on Tuesday, March 25, will highlight four pathologists describing their work using RNAscope technology: Dr. Rohit Mehra, Professor of Pathology at the University of Michigan, will describe TRIM63 mRNA as a surrogate marker in translocation-associated renal cell carcinoma, as an option to traditional DNA FISH. Dr. Vikram Deshpande, Professor of Pathology at Beth Israel Deaconess Medical Center, will detail how albumin mRNA can be a superior marker to secreted protein in primary and secondary liver tumors. Dr. Brooke Howitt, Associate Professor of Pathology at Stanford University, will present advances in the in situ detection of point mutations in molecularly defined gynecologic tumors. Dr. Gregory Bean, Associate Professor of Pathology at Stanford University, will describe the direct detection of mRNA from CRTC1/3::MAML2 translocations, as alternatives to MAML2 FISH, in the identification of mucoepidermoid carcinomas and hidradenomas. "We've made exciting advancements on in situ hybridization methods enabling novel applications in pathology laboratories," commented Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment. "This conference session highlights the frontier of clinical and translational research by leading pathologists using the latest RNAscope technologies for detecting the molecular underpinnings of disease." For Research Use Only. Not intended for use in diagnostic procedures. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube. About Bio-Techne Corporation (NASDAQ: TECH)Contact: David Clair, Vice President, Investor Relations & Corporate Development[email protected] 612-656-4416 SOURCE Bio-Techne Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News